Higher Tisagenlecleucel Doses May Improve Outcomes in Youth With B-ALL
Overall, event-free, relapse-free survival improved in patients receiving higher doses of tisagenlecleucel, with no increased toxicity
Oncology
Cancer Risk Higher for Men vs Women at Most Shared Anatomic Sites
The proportion of excess cancer risk in men that was explained by risk factors was modest, ranging from 50 to 11 percent
New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer
The approval was based on data from the phase 3 ARASENS trial.
Enhertu Approved for HER2-Low Metastatic Breast Cancer
The approval was based on data from a phase 3 trial that included adults with unresectable or metastatic HER2-low breast cancer who had previous lines of chemotherapy.
HPV Vaccination May Cut Risk for CIN2+ Recurrence
Effect estimate stronger for CIN2+ for disease related to HPV subtypes HPV 16 or HPV 18
New Tablet Formulation of Calquence Approved for CLL, SLL, MCL
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules.
Recurrent NMIBC Effectively Treated With Salvage Valrubicin+Docetaxel
Investigators studied the effect of sequential valrubicin and docetaxel in patients with recurrent NMIBC following treatment with intravesical bacillus Calmette-Guérin and/or gemcitabine-docetaxel.
Pembrolizumab Combos Miss Primary Endpoints in Liver, Prostate Cancer Trials
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
Many Online Pharmacies Sell Imatinib Without Prescription
23 percent of pharmacies selling imatinib online did not include drug-related warnings on their websites
